Original Research Article

Clinico-bacteriological profile and antibiogram of *Staphylococcus epidermidis* with special emphasis on Methicillin resistance and hospital acquired infections in a tertiary care center south India

Uma Chikkaraddi¹, Namratha W Nandihal¹,* , Smitha N R²

¹Dept. of Microbiology, Karnataka Institute of Medical Sciences, Hubballi, Karnataka, India
²Primary Health Center, Kuppur, Karnataka, India

**A R T I C L E I N F O**

**Article history:**
Received 16-01-2022
Accepted 21-01-2022
Available online 11-04-2022

**Keywords:**
MRSE
CoNS
Cefoxitin
Blood
Device

**ABSTRACT**

**Background:** *Staphylococcus epidermidis* is a normal commensal of the skin and mucous membrane of humans and animals. Despite the growing importance of its pathogenesis especially in neonatal septicemia and device associated infections, it is still considered as insignificant isolate in the clinical practice. Hence, the present study is taken up to analyze the sources and risk factors of the isolates and to know their antibiogram along with occurrence of Methicillin resistant *S. epidermidis* (MRSE).

**Materials and Methods:** 150 clinically significant *S. epidermidis* isolates from various clinical specimens were considered in this study. Species identification was done by phenotypic methods. The antimicrobial susceptibility test and detection of Methicillin resistance were performed by Kirby-Bauer’s disc diffusion method as per CLSI guidelines.

**Results:** Among 150 *S. epidermidis* isolates, 78% were recovered from hospital acquired infections. They were commonly isolated in pediatric age group (30%) and among males (60.67%). Total of 34.67% were isolated from pus samples followed by blood (25.33%). Most of the isolates were associated with multiple risk factors like hospitalization, prior antibiotic administration, foreign body in situ and ICU admission. Majority of the isolates expressed resistance towards Penicillin (93.33%), followed by Amoxicillin-Clavulanic acid (76%), Cotrimoxazole (71.33%), Fluoroquinolones (64%), Gentamicin (60%) and Erythromycin (55.33%). Resistance against Amikacin (16.67%), Tetracycline (9.3%) and Linezolid (0.67%) was low. All isolates were sensitive to Vancomycin. Inducible Clindamycin resistance was 18% and MRSE was 68%.

**Conclusion:** Clinical importance and emergence of drug resistance among *S. epidermidis* infections is growing with the advent of advanced medicine. This warrants the need to implement simple laboratory methods for species identification of the *S. epidermidis* and to determine the antibiotic resistant patterns on routine basis. Clinical correlation of the isolate is crucial to rule out the colonizers and contaminants.

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprint@ipinnovative.com

1. Introduction

*Staphylococcus epidermidis*; a Coagulase Negative Staphylococcus (CoNS), is Gram-positive cocci that occurs predominantly in ‘grape-like’ clusters. It is non-motile, non-spore forming and facultative anaerobe.¹

Originally, of all the staphylococci, only *Staphylococcus aureus* was considered pathogenic and all other species were grouped under CoNS and were considered nonpathogenic commensals on skin and mucous membranes of humans and other organisms.²,³

The commonest resident staphylococcal species on human skin is *S. epidermidis*. The largest populations (c.
$10^4$–$10^6$ cfu/cm$^2$) are found in regions of the skin with large numbers of pilosebaceous units and sweat glands and on the skin and mucous membranes surrounding openings to the body surface.\(^1\)

*S. epidermidis* possesses several virulence factors like Exopolysaccharide slime, Fibrinogen binding protein (Fbe), Extracellular matrix binding protein (Embp), Fatty Acid Modifying Enzyme (FAME) and Lipases.\(^4\) It has certain adaptations such as the down-regulation of Nucleic Acid (NA), proteins and cell wall biosynthesis and biofilm formation.\(^5\)

Host factors that often lead to infections with *S. epidermidis* include: breaches in natural mucocutaneous barriers due to surgery, trauma or inflammation, prior exposure to antibiotics and immunosuppression.\(^3\) Although host defects are clearly important in the pathogenesis, the most important factor contributing to the increasing number of nosocomial CoNS infections is the presence of indwelling prosthetic devices in both compromised and uncompromised hosts. Biofilm is a very useful and powerful factor contributing to Foreign Body-Related Infections (FBRIs) of staphylococci also designated as Device Associated Healthcare-Associated Infections (DA-HAIs).\(^6,7\)

*S. epidermidis* is involved in the pathogenesis of various infections like native and prosthetic valve endocarditis, osteomyelitis, intravenous catheters infections, Catheter Associated Blood Stream Infections (CA-BSI), Central Nervous System infections, peritonitis in peritoneal dialysis patients, Ocular infections, Catheter Associated Urinary Tract Infections (CA-UTI) and variety of cutaneous lesions.\(^4\)

Innate and acquired immunity play an important role against *S. epidermidis* infection. Despite the presence of antibodies, it is difficult to clear *S. epidermidis*. This may be due to exopolymers that protect the bacteria from antibody recognition and lysis. Also, as it is a resident colonizer, the immune system might be less active against it.\(^5\)

Antibiotic resistance is a growing challenge in treating the infections caused by *S. epidermidis* as it tends to be more multidrug resistant. Penicillin-resistant *S. epidermidis* isolates, responsible for fatal subacute bacterial endocarditis, were being reported as early as 1949.\(^8\) Today, as a result of huge selection pressures, it is very rare to find Penicillin-susceptible *S. epidermidis* isolates (10%) among hospitalized patients.\(^4,7\) In recent studies, the prevalence of oxacillin resistant *S. epidermidis* isolates has reached about 80% or more. As occurs with MRSA, MRSE isolates are more often multidrug resistant than Methicillin susceptible ones.\(^7\) Studies have demonstrated conjugative transfer of Gentamicin resistance plasmids from CoNS to CoNS and from CoNS to *S. aureus*. That means CoNS, particularly *S. epidermidis*, may be a reservoir for antibiotic resistance genes in the hospital environment.

*S. epidermidis* along with *S. haemolyticus* has been found to be the commonest CoNS species exhibiting reduced susceptibility to Glycopeptides. These resistant isolates were reported long before the advent of the first *S. aureus* isolates with reduced Glycopeptide susceptibility, in 1997.\(^7\)

In view of increasing prevalence of *S. epidermidis* infections, the present study has been undertaken to study the clinical and microbiological profile of *S. epidermidis* and its antibiogram along with detection of methicillin resistance using conventional techniques in our set up.

2. Materials and Methods

This cross sectional study was carried out over a period of one year. *S. epidermidis* isolated from various clinical samples either in pure or mixed culture from urine/pus samples (not more than two organisms) were included in the study. Contamination was ruled out by repeated isolation and significant colony counts. Detailed patients' history was collected. Samples were processed as per standard microbiological procedure.\(^9,10\) Identification of *S. epidermidis* was done based on colony morphology on Chocolate agar, Gram stain and a set of biochemical reactions; that includes, Catalase activity, inability to produce coagulase enzyme, urease activity, susceptibility to Novobiocin, negative pyrrolidonylarylamidase test (PYR test), decarboxylation of ornithine and aerobic acid production from mannose. (Image-1) The antimicrobial susceptibility test was performed by Kirby-Bauer’s disc diffusion method using routine panel of antibiotics. Methicillin resistance was detected by using Cefoxitin (30µg) disc and Inducible Clindamycin resistance was detected by D-Test using Clindamycin (2µg) and Erythromycin (15µg). Standard reference strain of Staphylococcus aureus ATCC 25923 was included and parallel tests were carried out for quality control. Interpretation of the results was done using CLSI guidelines.\(^11\)

The resultant data was analyzed using descriptive statistics and presented in the form of tables.

3. Results

A total of 150 clinically significant *S. epidermidis* isolates from various clinical samples over a period of one year were considered in the present study, of which maximum of *S. epidermidis* were recovered from patients of 0 to 10 years (30.67%) followed by 21 to 30 years of age (19.33%) (Table 1). Male to female ratio is 1.54:1 (Table 1). 78% of *S. epidermidis* were isolated from hospital acquired infections and 22% from community acquired infections. Among hospital localities, 30% of total 150 isolates were recovered from intensive care units (Table 2). Maximum of *S. epidermidis* were yielded from pus samples (34.67%) followed by Blood (25.33%) and ear discharge (16.67%).
Among associated risk factors, as high as 78% of patients had history of hospitalization, 73.33% had history of prior antibiotic administration, 57% of patients had foreign body in situ, 45% were ICU patients, 9.33% of the patients were diabetic and various other risk factors that encountered in lesser frequency are listed in Table 4.

Table 1: Age and gender wise distribution of S. epidermidis isolates. (n=150)

| Age group | No. of isolates | Percentage |
|-----------|-----------------|------------|
| 0-1 year  | 28              | 18.67%     |
| 1-10 years| 18              | 12%        |
| 11-20 years| 10             | 6.67%      |
| 21-30 years| 29             | 19.33%     |
| 31-40 years| 16             | 10.67%     |
| 41-50 years| 15             | 10%        |
| 51-60 years| 15             | 10%        |
| 61-70 years| 13             | 8.67%      |
| 71-80 years| 05             | 3.33%      |
| 81-90 years| 01             | 0.67%      |
| Male      | 91              | 60.67%     |
| Female    | 49              | 39.33%     |

Table 2: Distribution of sources of S. epidermidis infections (n=150)

| Source  | No. of isolates | Percentage |
|---------|-----------------|------------|
| Out patient | 33            | 22%        |
| In patient  | 117           | 78%        |
| Wards    | 72             | 48%        |
| ICU      | 45             | 30%        |
| - NICU  | 26             | 17.33%     |
| - PICU  | 06             | 04%        |
| - SICU  | 05             | 3.33%      |
| - IOICU | 04             | 2.67%      |
| - MICU  | 04             | 2.67%      |

Fig. 1: Biochemical reactions of S. epidermidis

Among antibiotics maximum resistance was expressed against Amikacin (16.67%), Tetracycline (9.33%) and Linezolid (0.67%). All the 150 isolates were 100% sensitive to Vancomycin and Teicoplanin. Inducible Clindamycin resistance is seen in 18% of the isolates and Methicillin resistance was detected among 102 isolates of S. epidermidis accounting for 68% of MRSE.

4. Discussion

S. epidermidis is the most frequently isolated commensal species from human epithelia. It colonizes predominantly axillae, head and nares. However it is seen as an important opportunistic pathogen. It is the most frequent cause of nosocomial infections in particular; it represents the commonest source of infection on indwelling medical devices. A better understanding of the physiology of S. epidermidis is important to evaluate therapeutic strategies against S. epidermidis infections.

Present study has studied 150 clinically significant S. epidermidis isolates with respect to the demographic profile of the patients, source of infections and associated risk factors along with their antibiotic susceptibility testing and detection of Inducible Clindamycin and methicillin resistance using conventional methodology. Results are compared with the studies conducted across the country and globe.

Maximum of S. epidermidis were isolated from the age group of 0 to 10 years (30.67%) followed by 21 to 30 years (19.33%). 0 to 1 year age group alone accounted for 18.67%. Which shows that pediatric age group especially infants are at higher risk of infections with S. epidermidis. Similar results were observed in study conducted by Lopes N et al who isolated 24.4% of S. epidermidis isolates from children less 1 year of age group. Male preponderance is observed in the present study similar to the study done by Lopes N et al. S. epidermidis is isolated from all type of clinical samples of which maximum of isolates were recovered from pus samples (34.67%) followed by Blood (25.33%). Pus sample is the leading source of S. epidermidis in the studies conducted by Jayanthi RS et al (30.11%) and Choudary U et al (30.12%) and blood is second most common sample in a study conducted by Jayanthi RS et al (22.59%). However in a study conducted by C Roopa et al, 82.45% of S. epidermidis isolates are recovered from pus samples and contrastingly only 16.54% were recovered in the study conducted by Parashar S et al. Similarly blood is the commonest sample in a study conducted by Choudary U et al and it is less common sample in a study conducted by C Roopa et al (5.26%) and Asangi S et al (2%). Most of the blood cultures samples were received from NICU in the present study. In a study conducted by Farran CA Y et al, 53.9% of blood culture isolates were S. epidermidis and with greater proportion in early onset neonatal septicemia. Ahmed M M et al
Table 3: Sample wise distribution of *S. epidermis* isolates

| Samples                        | Total (n=150) | Hospital acquired (n=117) | Community acquired (n=33) |
|--------------------------------|------------|---------------------------|---------------------------|
|                                | No. of Isolates | %                         | No. | %                         | No. | %                         |
| Pus                            | 52          |                           |     |                           |     |                           |
| - Pyoderma                     | 15          | 10%                       | 41  | 35.04                     | 11  | 33.33                     |
| - Abscess                      | 10          | 6.67%                     |     |                           |     |                           |
| - Orthopedic implant in situ   | 09          | 6%                        |     |                           |     |                           |
| - Orthopedic implant in situ   | 08          | 5.33%                     |     |                           |     |                           |
| - Osteomyelitis                | 02          | 1.33%                     |     |                           |     |                           |
| - Burn wound infection         | 02          | 1.33%                     |     |                           |     |                           |
| - Diabetic foot                | 06          | 4%                        |     |                           |     |                           |
| Blood                          | 38          | 25.33%                    | 37  | 31.62                     | 01  | 3.03                      |
| Ear discharge                  | 25          | 16.67%                    | 06  | 5.13                      | 19  | 57.58                     |
| Sputum                         | 10          | 6.67%                     | 09  | 7.69                      | 01  | 3.03                      |
| CSF                            | 08          | 5.33%                     | 08  | 6.84                      | -   | -                         |
| Urine                          | 06          | 4%                        | 05  | 4.27                      | 01  | 3.03                      |
| Vaginal swab                   | 04          | 2.67%                     | 04  | 3.41                      | -   | -                         |
| Cervical swab                  | 02          | 1.33%                     | 02  | 1.71                      | -   | -                         |
| Device (CVP Tip)               | 02          | 1.33%                     | 02  | 1.71                      | -   | -                         |
| Throat swab                    | 01          | 0.67%                     | 01  | 0.86                      | -   | -                         |
| Ascitic fluid                  | 01          | 0.67%                     | 01  | 0.86                      | -   | -                         |
| Pleural fluid                  | 01          | 0.67%                     | 01  | 0.86                      | -   | -                         |

Table 4: Antibiotic resistance pattern of *S. epidermis* isolates

| Antibiotics               | Hospital acquired (n=117) | Community acquired (n=33) | Total number of Resistant isolates (n=150) |
|---------------------------|---------------------------|---------------------------|------------------------------------------|
|                           | No. | %     | No. | %     | No. | %     |
| Penicillin                | 117 | 100   | 23  | 69.7  | 140 | 93.33%|
| Amoxicillin / Clavulanic acid | 100 | 85.47 | 14  | 42.43 | 114 | 76%   |
| Cotrimoxazole             | 97  | 82.91 | 10  | 30.30 | 107 | 71.33%|
| Norfloxacin               | 88  | 75.21 | 06  | 18.18 | 96  | 64%   |
| Ciprofloxacin             | 87  | 74.36 | 08  | 24.24 | 95  | 63.33%|
| Gentamicin                | 82  | 70.09 | 08  | 24.24 | 90  | 60%   |
| Erythromycin              | 65  | 55.56 | 18  | 54.56 | 83  | 55.33%|
| Clindamycin               | 50  | 42.74 | 23  | 69.70 | 73  | 48.67%|
| Amikacin                  | 20  | 17.09 | 05  | 15.15 | 25  | 16.67%|
| Tetracycline              | 05  | 4.27  | 09  | 27.27 | 14  | 9.33% |
| Linezolid                 | 1   | 0.86  | 00  | 0     | 1   | 0.67% |
| Teicoplanin               | 00  | 0     | 00  | 0     | 00  | 0%    |
| Vancomycin                | 00  | 0     | 00  | 0     | 00  | 0%    |
| Cefoxitin                 | 95  | 81.2  | 07  | 21.2  | 102 | 68%   |
Table 5: Risk factors associated with *S. epidermidis* infection (n=150)

| Risk factors                        | No. of isolates | Percentage |
|-------------------------------------|-----------------|------------|
| Prior of antibiotic administration  | 110             | 73.33%     |
| Present History of surgery          | 31              | 20.67%     |
| ICU admission                       | 45              | 30%        |
| NICU                                | 26              | 17.33%     |
| PICU                                | 06              | 04%        |
| SICU                                | 05              | 3.33%      |
| OICU                                | 04              | 2.67%      |
| MICU                                | 04              | 2.67%      |
| Foreign body insitu                 | 57              | 38%        |
| I.V. Catheter                       | 29              | 19.33%     |
| Suture                              | 14              | 09.33%     |
| Orthopedic Implant                  | 09              | 06         |
| Urinary Catheter                    | 02              | 1.33       |
| CVP                                 | 02              | 1.33       |
| Abdominal Drain                     | 01              | 0.67       |
| Underlying condition                |                 |            |
| Diabetes Mellitus                   | 14              | 09.33%     |
| Burn                                | 02              | 1.33       |
| Pregnancy                           | 02              | 1.33       |
| COPD                                | 03              | 02         |
| Cancer                              | 03              | 02         |
| HIV Infection                       | 01              | 0.67       |
| Chronic Kidney Disease              | 02              | 1.33       |
| Pulm. TB                            | 01              | 0.67       |
| Liver cirrhosis                     | 01              | 0.67       |
| Hospitalized patients               | 117             | 78%        |

found 65.5% of Gram positive cocci causing Bacteremia and majority among them were *S. epidermidis* isolates similarly Lopes N et al\(^13\) recovered 60.5% of *S. epidermidis* from CA-BSI cases. Out of 52 pus samples, maximum were collected from pyoderma (15) and Abscesses (10) followed by Orthopedic implant associated wound infections (09), Surgical site infections (08) and Diabetic wound infections (06). In a study conducted by Jayanthi RS et al\(^14\) 30% of *S. epidermidis* were isolated from Post-Operative wound infections and in a study by Lopes N et al\(^13\) 5.8% of Surgical site infections were caused by *S. epidermidis* and 5% of burn wound infections were caused by *S. epidermidis* in a study conducted by Sharma L et al.\(^21\)

Present study noticed that only 4% of *S. epidermidis* were isolated from urine samples which is in good correlation with the study conducted by Choudary U et al\(^15\) however in many other studies\(^17,18,22\) relatively higher number of isolates were recovered from urine samples and Lopes N et al\(^13\) isolated 12.8% of *S. epidermidis* from CA-UTI cases. Frequency of CSF (5.33%) sample in the present study is similar to the results seen in the studies conducted by C Roopa et al\(^16\) and Golia et al.\(^22\)

Coming to the risk factors associated with *S. epidermidis* infections, most of the patients in the present study had more than one underlying risk factors, commonest being hospitalization (78%) and antibiotic therapy (73.33%) followed by foreign body in situ (57%) and ICU stay (45%). Study conducted by Lopes N et al\(^13\) also found out that 55.8% of the patients were under antibiotics therapy and Chabi R et al\(^23\) in their study recovered 46% of *S. epidermidis* isolates from hospital acquired infections.

Among antibiotics, maximum resistance was expressed against Penicillin (93.33%), similar results are seen in most of the studies.\(^18,22,23\) However Saradar SA et al\(^24\) and Farran CA et al\(^19\) showed that all 100% of their isolates being resistant to Penicillin. Resistance against Amoxicillin-Clavulanic acid (76%) is comparable to the study done by Saradar SA et al\(^24\) and contrasting Golia et al\(^22\) observed only 21% resistance. 71.33% isolates were resistant to Cotrimoxazole in the present study. Correlating results are seen in the studies done by Chabi R et al\(^23\) and Saradar SA et al.\(^24\) contrasting results are shown in the studies done by Seetha KS et al.\(^25\) and Farran CA et al.\(^19\) Unfortunately next highest resistance was seen against two most important alternative antibiotic options in MRSE infections i.e Fluoroquinolones (64%) and Gentamicin (60%). Similar pattern is seen in Chabi R et al\(^23\) and Farran CA et al\(^19\) studies. However in most of the other studies.\(^22,25,26\) Gentamicin is shown as one of the most effective antibiotics and in our study Amikacin (16.67%) and Tetracycline (9.3%) turns out to be the effective therapeutic options against *S. epidermidis* infections.
is similar to the studies done by Ganti et al.26 and Seetha KS et al.,25 but Chabi R et al.23 showed 91.3% of resistance and contrastingly in a study done by Saradar SA et al.24 100% isolates were sensitive to Tetracycline. 55.33% isolates are resistant to Erythromycin in present study which is in correlation with studies done by Asangi S et al.18 and Seetha KS et al.,25 but not in correlation with studies done by Chabi R et al.23 and Ganti et al.26 Only one out of 150 isolates is resistant to Linezolid in the present study whereas few other studies18,22,26 show around 9% of resistance against Linezolid. Fortunately none of the 150 isolates is resistant to Linezolid in the present study. Prevalence of MRSE in our study is considerably high (68%). Similar occurrence is seen in the studies done by Golia et al (64.5%)22 and Asangi S et al (65%)18 in contrast to a study conducted by C Roopa et al (21%).16 Variable Prevalence of MRSE is seen in various studies.17,23–29

The present study has included only clinically significant S. epidermidis isolates. Species identification and antibiotic susceptibility tests were performed using conventional methodology that can be reproduced in any other laboratories. Detailed clinical history regarding underlying risk factors and demographic profile is analyzed to correlate the significance and pathogenicity of the isolate and the data can be used in formulating strategies on prevention and control of the hospital acquired S. epidermidis infections. As the study was conducted over a period of one year which is considerably longer, hence the results can be generalized and data may be utilized in policy making on routine surveillance cultures, empirical antibiotic policies and other control measures

5. Limitations
1. Present study focuses mainly on species identification and antibiogram of S. epidermidis, further study to ascertain the pathogenic significance like biofilm productions, detection of genes contributing for the virulence and antibiotic resistance would have made sense.
2. Vancomycin susceptibility is tested by disc diffusion method and MIC detection was not performed.

6. Conclusions
S. epidermidis is like a double edged sword as it is always confusing for Microbiologists whether to report it or not, and will always end up in reporting with a comment as “The isolate could be a skin commensal/contaminant”. Proper history, appropriate sample collection and repeated isolation confirm it’s significance. Present study throws a light on importance of patient’s history and significance of identification of S. epidermidis to species level in ascertaining the pathogenicity. Multidrug resistant strains of S. epidermidis higher rate of MRSE alarms that in vitro antibiotic susceptibility is must in all cases. That will guide the clinicians in treating the infected patients. There should be constant surveillance to detect emergence of Glycopeptide resistance. High degree of suspicion in addition to good infection control practices, the rational use of antimicrobial agents is one of the major steps in preventing S. epidermidis infections and antibiotic resistance.

7. Source of Funding
None.

8. Conflict of Interest
None.

References
1. Topley WWC, Wilson SGS. Bacteriology. In: Topley and Wilson’s Microbiology and Work Microbial Infections; 2007. p. 3–64.
2. Klosk WE, Bannerman TL. Update in clinical significance of Coagulase negative Staphylococci. Clin Microbiol Rev 1994;7:1:117–40.
3. Pfaller MA, Herwaldt LA. Laboratory, clinical and epidemiological aspects of CoNS. Clin Microbiol Rev. 1988;1(3):281–99.
4. Konemans WE, Allen DS, Janda MW. Color Atlas and Textbook of Diagnostic Microbiology. Philadelphia: Lippincott; 1997. p. 539–66.
5. Otto M. Staphylococcus epidermidis: the ‘accidental’ pathogen. Nat Rev Microbiol. 2009;7(8):555–67.
6. Toba FA, Akashi H, Arrecubita, Lowy FD. Role of biofilm in Staphylococcus aureus and Staphylococcus epidermidis ventricular assist device driveline infections. J Thorac Cardiovasc Surg. 2011;141(5):1259–64.
7. Becker K, Heilmann C, Peters G. Coagulase Negative Staphylococci. Clin Microbiol Rev. 2014;27(4):870–26.
8. Griffith GC, Levinson DC. Subacute bacterial endocarditis; a report on 57 patients treated with massive doses of penicillin. Calif Med. 1949;71(6):403–8.
9. Forbes BA. Bailey and Scott’s “Diagnostic Microbiology. 11th ed. United States: Mosby; 2002. p. 285–96.
10. Collee JG, Mackie TJ, Mccartney JE. Mackie & Mccartney practical medical microbiology. New York: Churchill Livingstone; 1996.
11. Performance Standards for Antimicrobial Susceptibility Testing; 20th Informational Supplement, Clinical and Laboratory Standards Institute (CLSI), M100-S24: Vol. 30, No.1. Wayne, PA: Clinical and Laboratory Standards Institute 2016.
12. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from. Am J Infect Control. 1992;32(8):470–85.
13. Lopes N, Freitas AI, Ramos H, and CV. S. epidermidis Isolates from a Tertiary Care Portuguese Hospital Show Very High Antibiotic Non-Susceptible Rates and Significant Ability to Form Biofilms. Appl Microbiol. 2021;1:150–61.
14. Jayanthi RS, Jomy J. Phenotypic Characterization of Clinically Significant Coagulase Negative Staphylococci and Their Susceptibility Pattern in a Tertiary Care Hospital. Int J Curr Microbiol App Sci. 2015;4(4):647–52.
15. Choudhary U, Arora B, Sharma M. The prevalence of Methicillin resistant Coagulase negative Staphylococcus in a tertiary care hospital in North India. J Infect Dis Antimicrob Agents. 2008;25(1):13–7.
16. Roopa C, Biradar S. Incidence and Speciation of Coagulase Negative Staphylococci Isolates from Clinically Relevant Specimens with their Antibiotic Susceptibility Patterns. Int J Curr Microbiol App Sci. 2015;4(9):975–80.
17. Parashar S. Significance of Coagulase Negative Staphylococci with Special Reference to Species Differentiation and Antibiogram. Indian Med Gazette. 2014;148(7):255–8.
18. Asangi SY, Mariraj J, Sathyarayanan MS, Nagabhushan R. Speciation of clinically significant Coagulase Negative Staphylococci and their antibiotic resistant pattern in a tertiary care hospital. *Int J Biol Med Res*. 2011;2:735–9.

19. Farran CE, Sekar A, Balakrishnan A, Shanmugam S, Arumugam P, Gopalswamy J. Prevalence of biofilm producing Staphylococcus epidermidis in the healthy skin of individuals in Tamil Nadu, India. *Indian J Med Microbiol*. 2013;31:19–23.

20. Ahmed MM, Bahlas S. Bacteriological profile and antimicrobial resistance patterns of clinical bacterial isolates in a University Hospital. *Travel Med Infect Dis*. 2009;7(4):235–8.

21. Sharma L, Srivastava H, Pipal DK, Dhawan R, Purohit PM, Bhargava A. Bacteriological profile of burn patients and antimicrobial susceptibility pattern of burn wound isolates. *Int Surg*. 2017;4(3):1019–23.

22. Golia S, Telsang DB, Kamath B, Kamath ASB, Tiwari D. Speciation of clinically significant coagulase negative staphylococci and their antibiotic resistant patterns in a tertiary care hospital. *Int J Res Med Sci*. 2015;3(5):1242–6.

23. Chabi R, Momtaz H. Virulence factors and antibiotic resistance properties of the Staphylococcus epidermidis strains isolated from hospital infections in Ahvaz. *Trop Med Health*. 2019;47:56–56.

24. Sardar SA, Singh M, Basireddy S, Ali S, Kabra V. Coagulase Negative Staphylococci among Clinical Isolates in a Tertiary Care Centre. *Int J Pharm Bio Sci*. 2015;6(1):229–36.

25. Seetha KS, Santosh PK, Shivanand PG. Study of coagulase negative staphylococci isolated from blood and CSF cultures. *Indian J Pathol Microbiol*. 2000;43(1):41–5.

26. Gunth R, Arava D, Koppad R. Speciation of Coagulase Negative Staphylococci and Their Antibiogram. *IOSR J Dent Med Sci*. 2016;15(1):28–31.

27. Prasad S, Nayak N, Satpathy G, Nag HL, Venkatesh P, Ramakrishnan S, et al. Molecular & phenotypic characterization of Staphylococcus epidermidis in implant related infections. *Indian J Med Res*. 2012;136(3):483–90.

28. Karigoudar RM, Nagamoti MB. Characterization and Antibiotic Susceptibility Pattern of Coagulase Negative Staphylococci with Special Reference to Methicillin Resistance. *Int J Curr Microbiol App Sci*. 2016;5(3):114–20.

29. Guo Y, Ding Y, Liu L, Shen X, Hao Z, Duan J, et al. Antimicrobial susceptibility, virulence determinants profiles and molecular characteristics of Staphylococcus epidermidis isolates in Wenzhou, eastern China. *BMC Microbiol*. 2009;9(1):157.

**Author biography**

**Uma Chikkaraddi,** Tutor

**Namratha W Nandihal,** Associate Professor

**Smitha N R,** Medical Officer

**Cite this article:** Chikkaraddi U, Nandihal NW, Smitha N R. Clinico-bacteriological profile and antibiogram of Staphylococcus epidermidis with special emphasis on Methicillin resistance and hospital acquired infections in a tertiary care center south India. *Indian J Microbiol Res* 2022;9(1):34-40.